Home
Per Eystein Lønning's picture

Per Eystein Lønning

Professor
  • E-mailPer.Lonning@uib.no
  • Phone+47 55 97 20 10+47 55 97 20 27
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning is the head of the breast cancer research group at Mohn cancer research laboratory. he has a continuous work record in cancer therapy and science since 1982. He was employed as a consultant in oncology at Haukeland University Hospital in 1990, and became professor at the University of Bergen in 1992. The breast cancer group currently includes about 20 members. The work is centered on translational research in breast cancer; the group however also runs projects related to colorectal cancers and melanomas. The team include senior researchers 7 postdocs / PhD candidates as well as technical staff members in the laboratory but also physicians seeing patients at the Department of Oncology, several of whom in addition work part-time on their projects in the laboratory. Professor Lønnings main area of interest has been mechanism related to therapy failure in the area of endocrine as well as chemotherapy for breast cancer. In addition, he has had an interest in genetic and epigenetic cancer risk factors. His current main field of research relates to chemotherapy resistance.

Academic article
  • 2013. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 12 pages.
  • 2013. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis. 867-876.
  • 2013. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 12 pages.
  • 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 2790-2797.
  • 2013. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE.
  • 2012. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 501-510.
  • 2012. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European Journal of Cancer. 1988-1996.
  • 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 11 pages.
  • 2012. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR in Biomedicine. 369-378.
  • 2012. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology.
  • 2012. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 13 pages.
  • 2012. MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLOS ONE. 6 pages.
  • 2012. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 12 pages.
  • 2012. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine. 1033-1042.
  • 2012. Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. European Journal of Endocrinology. 941-949.
  • 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 6 pages.
  • 2012. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology. 69-75.
  • 2012. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. Journal of Clinical Oncology. 709-717.
  • 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 1533-1545.
  • 2012. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 8 pages.
  • 2011. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell. 273-282.
  • 2011. Recent data on intratumor estrogens in breast cancer. Steroids. 786-791.
  • 2011. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer(dagger). Annals of Oncology. 2208-2215.
  • 2011. Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLOS ONE. 10 pages.
  • 2011. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. OncoTarget. 251-258.
  • 2011. Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials. Acta Oncologica. 1068-1074.
  • 2011. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 9-12.
  • 2011. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription.
  • 2011. Alterations of the retinoblastoma gene in metastatic breast cancer. Clinical and Experimental Metastasis. 319-326.
  • 2010. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 2127-2133.
  • 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
  • 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
  • 2010. Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Molecular Cancer. 13 pages.
  • 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
  • 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
  • 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
  • 2010. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 pages.
  • 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
  • 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
  • 2010. Are current development programs realising the full potential of new agents? Breast Cancer Research. 4 pages.
  • 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
  • 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research.
  • 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 5331-5339.
  • 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
  • 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
  • 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
  • 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 987-997.
  • 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 15 pages.
  • 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
  • 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
  • 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
  • 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
  • 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 7267-7278.
  • 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. viii3-viii7.
  • 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
  • 2006. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 7735-7740.
  • 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
  • 2006. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology. 217-225.
  • 2004. Understanding chemoresistance- the ultimate challenge in cancer therapy. Breast Cancer Online.
  • 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • 2004. Oestrogen suppression; lessons from clinical studies. Baillière's Best Practice & Research. Clinical Endocrinology & Metabolism. 33-45.
  • 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • 2004. Mutation of GATA3 in human breast tumors. Oncogene. 7669-7678.
  • 2004. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer. Clinical Cancer Research. 3438-3443.
  • 2004. Genes causing inherited cancer as beacons to identify the mechanism of chemoresistance. Trends in Molecular Medicine. 113-118.
  • 2004. Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind study. New England Journal of Medicine. 1081-1092.
  • 2004. Cell-type specific responses to chemotherapeutics in breast cancer. Cancer Research. 4218-4226.
  • 2004. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene. 8535-8544.
  • 2004. Alternative splicing and mutation status of CHEK2 in stag III breast cancer. Oncogene. 8535-8544.
  • 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • 2001. The insulinlike growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism. 227-233.
  • 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • 2001. Influence of TP53 gene alterations and cErbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research. 2505-2512.
  • 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 10869-10874.
  • 2000. Screening breast cancer patients for Norwegian ATM mutations. British Journal of Cancer. British Journal of Cancer. 1650-53.
  • 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • 2000. Genetic variants of CYP19 (arometase) and breast cancer risk. Oncogene. 1329-1333.
  • 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • 1999. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Research. 2825-2828.
  • 1999. CYP 17 and breast cancer risk; the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • 1998. Microencapsulated Octreotide in Advanced Gastrointestinal and Pancreatic Cancer: a Phase I Study. British Journal of Cancer. 14-20.
  • 1998. Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
  • 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • 1998. Influence of droloxifene on metastatic breast cancer as first line endocrine treatment. Acta Oncologica. 365-368.
  • 1998. Influence of dexaminoglutethimide, optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patie. Journal of Clinical Endocrinology and Metabolism. 2687-2693.
  • 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • 1998. Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
  • 1998. Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas. 259-265.
  • 1997. Subgroups of TP53 mutations may predict clinical behaviour and therapy response in breast and ovary cancer patients. Breast and Ovarian Cancer: Molecular Markers of Risk: Progression and new Therapeutic strategies, Pisa, Italy..
  • 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1997. Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • 1996. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
  • 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Specific p53 mutations are associated with de novo ressistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • 1996. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research. 1515-1521.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • 1996. Pharmacology of new aromatase inhibitors. Breast. 202-208.
  • 1996. Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • 1996. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
  • 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • 1996. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism. 2216-2221.
  • 1996. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • 1996. Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
  • 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • 1995. Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • 1995. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment. 287-297.
  • 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • 1995. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • 1995. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 193-195.
  • 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • 1995. Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • 1995. Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • 1994. Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. European Journal of Cancer. 106-111.
  • 1994. Systemic therapy in breast cancer: Efficacy and cost utility. Pharm Econ. 198-212.
  • 1994. Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
  • 1994. Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • 1994. Combined treatment with 4-hydroxyandrostendione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. British Journal of Cancer. 1171-1175.
  • 1993. Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
  • 1993. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • 1993. Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
  • 1993. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
  • 1990. Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
  • 1988. Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet. Cancer Chemotherapy and Pharmacology. 313-318.
Academic lecture
  • 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Academic anthology/Conference proceedings
  • 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Abstract
  • 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Academic literature review
  • 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. 1580-1583.
  • 2015. Estradiol measurement in translational studies of breast cancer. 26-31.
  • 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 681-700.
  • 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. 5315-5330.
  • 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. R183-R201.
  • 2012. P53 and its molecular basis to chemoresistance in breast cancer. S23-S30.
  • 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 503-514.
  • 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. 4948-4958.
  • 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. 1825-1836.
  • 2010. Molecular basis for therapy resistance. 284-300.
  • 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? 527-535.
  • 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 6-22.
  • 2009. Additive endocrine therapy for advanced breast cancer - back to the future. 1092-1101.
  • 2008. Indications and limitations of third-gene ration aromatase inhibitors. 723-739.
  • 2007. Breast cancer prognostication and prediction in the postgenomic era. 1293-1306.
  • 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. 53-61.
  • 2004. Aromatase inhibitors in breast cancer. 179-189.

More information in national current research information system (CRIStin)

Fields of competence